Drug Profile

Research programme: BACE1 protein inhibitors - Merck and Co

Alternative Names: SCH-1359113; SCH-1682496; SCH-785532

Latest Information Update: 02 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Merck & Co; Sunesis Pharmaceuticals
Developer Merck & Co
Class Guanidines; Hydantoins; Macrocyclic compounds; Piperidines; Pyrimidinones; Small molecules; Sulfones
Mechanism of Action BACE1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Alzheimer's disease

Most Recent Events

24 Feb 2021 Sunesis Pharmaceuticals has been merged with Viracta Therapeutics to form Viracta Therapeutics
04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
10 Apr 2008 Research phase development is ongoing

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com